| 000 | 01812 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518014407.0 | ||
| 264 | 0 | _c20191212 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a1524-4539 | ||
| 024 | 7 |
_a10.1161/CIRCULATIONAHA.118.036710 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVan der Wall, Sake J | |
| 245 | 0 | 0 |
_aIdarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. _h[electronic resource] |
| 260 |
_bCirculation _c02 2019 |
||
| 300 |
_a748-756 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadverse effects |
| 650 | 0 | 4 |
_aAnticoagulants _xadverse effects |
| 650 | 0 | 4 |
_aDabigatran _xadverse effects |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGastrointestinal Hemorrhage _xepidemiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 650 | 0 | 4 |
_aVenous Thromboembolism _xdrug therapy |
| 650 | 0 | 4 |
_aVitamin K _xantagonists & inhibitors |
| 700 | 1 | _aLopes, Renato D | |
| 700 | 1 | _aAisenberg, James | |
| 700 | 1 | _aReilly, Paul | |
| 700 | 1 | _avan Ryn, Joanne | |
| 700 | 1 | _aGlund, Stephan | |
| 700 | 1 | _aElsaesser, Amelie | |
| 700 | 1 | _aKlok, Frederikus A | |
| 700 | 1 | _aPollack, Charles V | |
| 700 | 1 | _aHuisman, Menno V | |
| 773 | 0 |
_tCirculation _gvol. 139 _gno. 6 _gp. 748-756 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/CIRCULATIONAHA.118.036710 _zAvailable from publisher's website |
| 999 |
_c29198994 _d29198994 |
||